Exploring the Diagnostic Biomarkers of Cognitive Disorders in China

Launched by CUIBAI WEI，CLINICAL PROFESSOR · May 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to identify early signs of dementia and related cognitive disorders in people from China. Researchers aim to find biological markers, or "biomarkers," which are changes in the body that can signal the presence or risk of dementia. By creating a large database of information from participants, they hope to improve early diagnosis and treatment, ultimately leading to better outcomes for individuals experiencing cognitive decline.

To participate in this trial, you need to be between 40 and 90 years old and have noticed some decline in your thinking or memory skills. You should be able to communicate in Chinese, and both you and your family will need to understand and agree to be part of the study. Participants will undergo various assessments to track their cognitive health over time. It’s important to note that those with certain other neurological or systemic diseases, or who cannot undergo certain tests, will not be eligible to join. This research is crucial for advancing our understanding of dementia and improving care for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patients aged ≥40 and ≤90years;
• • Chief complaint or others describe a cognitive decline;
• • Ability to communicate in Chinese;
• • The patients and their families were informed and signed the informed consent.
• Exclusion Criteria:
• • MMSE\<10;
• • There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);
• • There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
• • Suffering from a disease that cannot cooperate with the completion of cognitive examination;
• • There are contraindications to nuclear magnetic resonance;
• • There is mental and neurodevelopmental delay;
• • Refuse to draw blood;
• • Refuse to sign the informed consent.

Trial Officials